Agree for x-US markets, but in the US, there is enough capacity to treat a large number of patients quickly. Even without assuming any expansion in the number of HCV treaters (which will likely occur) just reducing the tx length to 12 weeks and removing IFN and associated side-effects will more than double current treatment capacity. So I do expect the same parabolic boom and bust launch trajectory as we've been seeing historically for this category.
Market Data 
Markets 
AI
